TY - JOUR
T1 - Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer
T2 - Implications for immunotherapy
AU - Akcakanat, Argun
AU - Kanda, Tatsuo
AU - Tanabe, Tadashi
AU - Komukai, Shintarou
AU - Yajima, Kazuhito
AU - Nakagawa, Satoru
AU - Ohashi, Manabu
AU - Hatakeyama, Katsuyoshi
PY - 2006/1/1
Y1 - 2006/1/1
N2 - Cancer/testis antigens (CTAs) elicit immune response in cancer patients and are therefore targets of immunotherapy. Current information on CTA expression is primarily based on mRNA assays and little is known about their expression at the protein level. The objectives of our study are to analyze GAGE, NY-ESO-1, MAGE-A and SSX protein expression in esophageal cancer and to correlate their expression patterns with clinicopathologic parameters and survival. We examined CTA protein expression in 213 patients with esophageal cancer by immunohistochemistry. Antigen-positive tumors were evaluated once and antigen-negative tumors were evaluated 3 times by examining different parts of the cancer specimen. GAGE, NY-ESO-1 and MAGE-A were heterogeneously expressed in 42 (20%), 44 (21%) and 111 (52%) tumors, respectively, whereas SSX expression was not detected. Of the 126 (59%) patients expressing CTAs, 70 (33%) expressed 1, 41 (19%) expressed 2 and 15 (7%) expressed 3 antigens. The expression of MAGE-A was correlated with those of GAGE (p=0.001) and NY-ESO-1 (p=0.002), and the expression of GAGE was correlated with that of NY-ESO-1 (p=0.002). One hundred fifty-six (79%) sections were positively stained in the first evaluation, whereas 37 (19%) and 4 (2%) positive sections were identified in the second and third evaluations, respectively. Particularly, MAGE and GAGE expression showed overlaps. GAGE, NY-ESO-1 and MAGE-A protein expression was not correlated with the disease progression, TNM factors or survival. The detection of immunonegative cells in every specimen suggests addition of other drugs such as 5-aza-2′-deoxycytidine to increase the therapeutic effect of CTA-specific cancer vaccines.
AB - Cancer/testis antigens (CTAs) elicit immune response in cancer patients and are therefore targets of immunotherapy. Current information on CTA expression is primarily based on mRNA assays and little is known about their expression at the protein level. The objectives of our study are to analyze GAGE, NY-ESO-1, MAGE-A and SSX protein expression in esophageal cancer and to correlate their expression patterns with clinicopathologic parameters and survival. We examined CTA protein expression in 213 patients with esophageal cancer by immunohistochemistry. Antigen-positive tumors were evaluated once and antigen-negative tumors were evaluated 3 times by examining different parts of the cancer specimen. GAGE, NY-ESO-1 and MAGE-A were heterogeneously expressed in 42 (20%), 44 (21%) and 111 (52%) tumors, respectively, whereas SSX expression was not detected. Of the 126 (59%) patients expressing CTAs, 70 (33%) expressed 1, 41 (19%) expressed 2 and 15 (7%) expressed 3 antigens. The expression of MAGE-A was correlated with those of GAGE (p=0.001) and NY-ESO-1 (p=0.002), and the expression of GAGE was correlated with that of NY-ESO-1 (p=0.002). One hundred fifty-six (79%) sections were positively stained in the first evaluation, whereas 37 (19%) and 4 (2%) positive sections were identified in the second and third evaluations, respectively. Particularly, MAGE and GAGE expression showed overlaps. GAGE, NY-ESO-1 and MAGE-A protein expression was not correlated with the disease progression, TNM factors or survival. The detection of immunonegative cells in every specimen suggests addition of other drugs such as 5-aza-2′-deoxycytidine to increase the therapeutic effect of CTA-specific cancer vaccines.
KW - Immunohistochemistry
KW - Prognosis
KW - Tumor antigens
UR - http://www.scopus.com/inward/record.url?scp=27944486675&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27944486675&partnerID=8YFLogxK
U2 - 10.1002/ijc.21219
DO - 10.1002/ijc.21219
M3 - Article
C2 - 16003736
AN - SCOPUS:27944486675
SN - 0020-7136
VL - 118
SP - 123
EP - 128
JO - International journal of cancer
JF - International journal of cancer
IS - 1
ER -